The prevention and treatment of venous thromboembolism in pregnancy

Expert Review of Cardiovascular Therapy

Volumn 15, Issue 5, 2017, Pages 397-402

  Villani, Michela ^a   Ageno, Walter ^b   Grandone, Elvira ^a   Dentali, Francesco ^b  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b OSPEDALE DI CIRCOLO   (Italy)

Author keywords

Heparin; postpartum period; pregnancy; thromboprophylaxis; venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; FEMALE; HUMAN; META ANALYSIS (TOPIC); PREGNANCY; PREGNANCY DISORDER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW (TOPIC); THROMBOSIS PREVENTION; VENOUS THROMBOEMBOLISM; INCIDENCE; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RISK FACTOR;

ANTICOAGULANTS; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INCIDENCE; PREGNANCY; PREGNANCY COMPLICATIONS, CARDIOVASCULAR; RISK FACTORS; VENOUS THROMBOEMBOLISM;

EID: 85018921338     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1080/14779072.2017.1319279     Document Type: Review

References (62)

1. Heit JA, Kobbervig CE, James AH, et al. Trends in the incidence of venous thromboembolism during pregnancy or postpartum:a 30-year population-based study. Ann Intern Med. 2005;143(10):697–706. PubMed:16287790.
2. Gherman RB, Goodwin TM, Leung B, et al. Incidence, clinical characteristics, and timing of objectively diagnosed venous thromboembolism during pregnancy. Obstet Gynecol. 1999;94(5 Pt 1):730–734. PubMed:10546719.
3. Lindqvist P, Dahlbäck B, Marŝál K., Thrombotic risk during pregnancy:a population study. Obstet Gynecol. 1999;94(4):595–599. PubMed:10511366.
4. Simpson EL, Lawrenson RA, Nightingale AL, et al. Venous thromboembolism in pregnancy and the puerperium:incidence and additional risk factors from a London perinatal database. BJOG. 2001;108(1):56–60. PubMed:11213005.
5. James AH, Jamison MG, Brancazio LR, et al. Venous thromboembolism during pregnancy and the postpartum period:incidence, risk factors, and mortality. Am J Obstet Gynecol. 2006;194(5):1311–1315. PubMed:16647915.• An interesting study about the epidemiology of pregnancy-related thromboembolic disease in US.
6. Andersen BS, Steffensen FH, Sørensen HT, et al. The cumulative incidence of venous thromboembolism during pregnancy and puerperium–an 11 year Danish population-based study of 63,300 pregnancies. Acta Obstet Gynecol Scand. 1998;77(2):170–173. PubMed:9512321.
7. Jacobsen AF, Skjeldestad FE, Sandset PM., Incidence and risk patterns of venous thromboembolism in pregnancy and puerperium–a register-based case-control study. Am J Obstet Gynecol. 2008;198(2):233.e1-7. PubMed:17997389.
8. McColl MD, Ramsay JE, Tait RC, et al. Risk factors for pregnancy associated venous thromboembolism. Thromb Haemost. 1997;78(4):1183–1188. PubMed:9364982.
9. Berg CJ, Atrash HK, Koonin LM, et al. Pregnancy-related mortality in the United States, 1987–1990. Obstet Gynecol. 1996;88(2):161–167. PubMed:8692494.
10. Anderson FA, Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151(5):933–938. PubMed:2025141.
11. Pomp ER, Lenselink AM, Rosendaal FR, et al. Pregnancy, the postpartum period and prothrombotic defects:risk of venous thrombosis in the MEGA study. J Thromb Haemost. 2008;6(4):632–637. PubMed:18248600.• A case-control study showing the important role of pregnancy and postpartum period in the risk of VTE.
12. Rova K, Passmark H, Lindqvist PG. Venous thromboembolism in relation to in vitro fertilization:an approach to determining the incidence and increase in risk in successful cycles. Fertil Steril. 2012;97(1):95–100. PubMed:22118992.
13. Henriksson P, Westerlund E, Wallén H, et al. Incidence of pulmonary and venous thromboembolism in pregnancies after in vitro fertilisation:cross sectional study. BMJ. 2013;346:e8632. PubMed:23321489.•• A cross sectional study demonstrating the increased risk of VTE in pregnancies after in vitro fertilisation.
14. Hansen AT, Kesmodel US, Juul S, et al. Increased venous thrombosis incidence in pregnancies after in vitro fertilization. Hum Reprod. 2014;29(3):611–617. PubMed:24399508.
15. Villani M, Dentali F, Colaizzo D, et al. Pregnancy-related venous thrombosis:comparison between spontaneous and ART conception in an Italian cohort. BMJ Open. 2015;5(10):e008213. PubMed:26443651.
16. Chan WS. The ‘ART’ of thrombosis:a review of arterial and venous thrombosis in assisted reproductive technology. Curr Opin Obstet Gynecol. 2009;21(3):207–218. PubMed:19276806.
17. Macklon NS, Greer IA. Venous thromboembolic disease in obstetrics and gynaecology:the Scottish experience. Scott Med J. 1996;41(3):83–86. PubMed:8807703.
18. Knight M. UKOSS. Antenatal pulmonary embolism:risk factors, management and outcomes. BJOG. 2008;115(4):453–461. PubMed:18201281.
19. Larsen TB, Sørensen HT, Gislum M, et al. Maternal smoking, obesity, and risk of venous thromboembolism during pregnancy and the puerperium:a population-based nested case-control study. Thromb Res. 2007;120(4):505–509. PubMed:17257657.
20. Gerhardt A, Scharf RE, Greer IA, et al. Hereditary risk factors of thrombophilia and probability of venous thromboembolism during pregnancy and the puerperium. Blood. 2016. [Epub ahead of print].
21. Hellgren M, Blombäck M. Studies on blood coagulation and fibrinolysis in pregnancy, during delivery and in the puerperium. I. Normal condition. Gynecol Obstet Invest. 1981;12(3):141–154. PubMed:7239349.
22. Greer IA. Thrombosis in pregnancy:maternal and fetal issues. Lancet. 1999;353(9160):1258–1265. PubMed:10217099
23. Macklon NS, Greer IA. The deep venous system in the puerperium:an ultrasound study. Br J Obstet Gynaecol. 1997;104(2):198–200. PubMed:9070138.
24. Macklon NS, Greer IA, Bowman AW. An ultrasound study of gestational and postural changes in the deep venous system of the leg in pregnancy. Br J Obstet Gynaecol. 1997;104(2):191–197. PubMed:9070137.
25. Holzgreve W, Carey JC, Hall BD. Warfarin-induced fetal abnormalities. Lancet. 1976;2(7991):914–915. PubMed:62152.
26. Wong V, Cheng CH, Chan KC. Fetal and neonatal outcome of exposure to anticoagulants during pregnancy. Am J Med Genet. 1993;45(1):17–21. PubMed:8418652.
27. Vitale N, De Feo M, De Santo LS, et al. Dose-dependent fetal complications of warfarin in pregnant women with mechanical heart valves. J Am Coll Cardiol. 1999;33(6):1637–1641. PubMed:10334435.
28. Cotrufo M, De Feo M, De Santo LS, et al. Risk of warfarin during pregnancy with mechanical valve prostheses. Obstet Gynecol. 2002;99(1):35–40. PubMed:11777507.• A study showing the risk for pregnancy complications in women with mechanical valve prostheses anticoagulated with warfarin.
29. Schaefer C, Hannemann D, Meister R, et al. Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study. Thromb Haemost. 2006;95(6):949–957. PubMed:16732373.
30. Bates SM, Greer IA, Middeldorp S, et al. American College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy:antithrombotic therapy and prevention of thrombosis, 9th ed:American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e691S–736S. PubMed:22315276.•• Useful guidelines for prevention and treatment of VTE during pregnancy.
31. Hoeltzenbein M, Beck E, Meixner K, et al. Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events:a case series from the German Embryotox Pharmacovigilance Centre. Clin Res Cardiol. 2016;105(2):117–126. PubMed:26195125.•• Interesting data on pregnancy outcome in women inadvertently exposed to rivaroxaban.
32. Dempfle CE. Minor transplacental passage of fondaparinux in vivo. N Engl J Med. 2004;350(18):1914–1915. PubMed:15115845.
33. Arya R. How I manage venous thromboembolism in pregnancy. Br J Haematol. 2011;153(6):698–708. PubMed:21501137.
34. Bates SM, Middeldorp S, Rodger M, et al. Guidance for the treatment and prevention of obstetric-associated venous thromboembolism. J Thromb Thrombolysis. 2016;41(1):92–128. PubMed:26780741.
35. Grandone E, Villani M, Tiscia GL. Aspirin and heparin in pregnancy. Expert Opin Pharmacother. 2015;16(12):1793–1803. PubMed:26155946.• A recent review on the use of antithrombotic drugs during pregnancy.
36. Ghidini A. Overview of low molecular weight heparin for preventative treatment of adverse obstetric outcomes related to abnormal placentation. Prenat Diagn. 2014;34(7):649–654. PubMed:24752745.
37. Dentali F, Grandone E, Rezoagli E, et al. Efficacy of low molecular weight heparin in patients undergoing in vitro fertilization or intracytoplasmic sperm injection. J Thromb Haemost. 2011;9(12):2503–2506. PubMed:21985211.•• A systematic review and meta-analysis of the literature showing the beneficial effect of LMWH on IVF/ICSI outcomes.
38. Grandone E, Villani M, Tiscia GL, et al. Clinical utility of antithrombotic prophylaxis in ART procedures:an Italian experience. Plos One. 2014;9(5):e97604. PubMed:24870449.
39. Grandone E, Villani M, Tiscia GL, et al. Clinical pregnancies and live births in women approaching ART:a follow-up analysis of 157 women after thrombophilia screening. Thromb Res. 2014;133(2):168–172. PubMed:24321417.
40. Grandone E, Villani M, Dentali F, et al. Low-molecular -weight heparin in pregnancies after ART–a retrospective study. Thromb Res. 2014;134(2):336–339. PubMed:24972844.
41. Bain E, Wilson A, Tooher R, et al. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev. 2014;2:CD001689.PubMed:24519568.
42. McLean KC, Bernstein IM. Brummel-Ziedins KE. Tissue factor-dependent thrombin generation across pregnancy. Am J Obstet Gynecol. 2012;207(2):135.e1-6. PubMed:22840726.
43. Dargaud Y, Hierso S, Rugeri L, et al. Endogenous thrombin potential, prothrombin fragment 1+2 and D-dimers during pregnancy. Thromb Haemost. 2010;103(2):469–471. PubMed:20024504.
44. James A. Committee on practice bulletins–obstetrics. Practice bulletin no. 123:thromboembolism in pregnancy. Obstet Gynecol. 2011;118(3):718–729. PubMed:21860313.• A useful document providing information on risk factors, diagnosis, management and prevention of pregnancy-related VTE.
45. Chan WS, Rey E, Kent NE. VTE in Pregnancy Guideline Working Group; Society of Obstetricians and Gynecologists of Canada. Venous thromboembolism and antithrombotic therapy in pregnancy. J Obstet Gynaecol Can. 2014;36(6):527–553. PubMed:24927193.•• A recent evidence-based document on diagnosis, treatment and thromboprophylaxis of pregnancy-related VTE.
46. Royal College of Obstetricians and Gynaecologists 2015. Green-top Guideline No. 37b. Thromboembolic disease in pregnancy and the puerperium:acute management. cited 2015 Jun10. Available from:https://www.rcog.org.uk/en/guidelines-research-services/guidelines/gtg37b/.•• Useful guidelines on acute management of pregnancy-related VTE.
47. Greer IA, Nelson-Piercy C. Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy:a systematic review of safety and efficacy. Blood. 2005;106(2):401–407. PubMed:15811953.• A systematic review showing the role of LMWH in the prevention and treatment of VTE during pregnancy.
48. Romualdi E, Dentali F, Rancan E, et al. Anticoagulant therapy for venous thromboembolism during pregnancy:a systematic review and a meta-analysis of the literature. J Thromb Haemost. 2013;11(2):270–281. PubMed:23205953.
49. Roeters van Lennep JE, Meijer E, Klumper FJ, et al. Prophylaxis with low-dose low-molecular-weight heparin during pregnancy and postpartum:is it effective? J. Thromb Haemost. 2011;9(3):473–480. PubMed:21232006.
50. Galambosi PJ, Ulander VM, Kaaja RJ. The incidence and risk factors of recurrent venous thromboembolism during pregnancy. Thromb Res. 2014;134(2):240–245. PubMed:24835671.
51. McLintock C, Brighton T, Chunilal S, et al. Councils of the Society of Obstetric Medicine of Australia and New Zealand; Australasian Society of Thrombosis and Haemostasis. Recommendations for the diagnosis and treatment of deep venous thrombosis and pulmonary embolism in pregnancy and the postpartum period. Aust N Z J Obstet Gynaecol. 2012;52(1):14–22. PubMed:21972999.• Useful recommendations for diagnosis and management of acute VTE during pregnancy.
52. Kearon C, Akl EA, Comerota AJ, et al. American College of Chest Physicians. Antithrombotic therapy for VTE disease:antithrombotic therapy and prevention of thrombosis, 9th ed:American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2Suppl):419S–94S. PubMed:22315268.
53. Linkins LA, Dans AL, Moores LK, et al. American College of Chest Physicians. Treatment and prevention of heparin-induced thrombocytopenia:antithrombotic therapy and prevention of thrombosis, 9th ed:American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141(2Suppl):e495S–530S. PubMed:22315270.
54. Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol. 2004;191(3):1024–1029. PubMed:15467584.
55. Jacobsen AF, Qvigstad E, Sandset PM. Low molecular weight heparin (dalteparin) for the treatment of venous thromboembolism in pregnancy. BJOG. 2003;110(2):139–144. PubMed:12618157.
56. Crowther MA, Spitzer K, Julian J, et al. Pharmacokinetic profile of a low-molecular weight heparin (reviparin) in pregnant patients. A prospective cohort study. Thromb Res. 2000;98(2):133–138. PubMed:10713314.
57. Rodie VA, Thomson AJ, Stewart FM, et al. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy:a case series. BJOG. 2002;109(9):1020–1024. PubMed:12269676.
58. Rey E, Rivard GE. Prophylaxis and treatment of thromboembolic diseases during pregnancy with dalteparin. Int J Gynaecol Obstet. 2000;71(1):19–24. PubMed:11044537.
59. Smith MP, Norris LA, Steer PJ, et al. Tinzaparin sodium for thrombosis treatment and prevention during pregnancy. Am J Obstet Gynecol. 2004;190(2):495–501. PubMed:14981396.
60. Patel JP, Green B, Patel RK, et al. Population pharmacokinetics of enoxaparin during the antenatal period. Circulation. 2013;128(13):1462–1469. PubMed:23940396.
61. Nelson-Piercy C, Powrie R, Borg JY, et al. Tinzaparin use in pregnancy:an international, retrospective study of the safety and efficacy profile. Eur J Obstet Gynecol Reprod Biol. 2011;159(2):293–299. PubMed:21945573.
62. Voke J, Keidan J, Pavord S, et al. British society for haematology obstetric haematology group. The management of antenatal venous thromboembolism in the UK and Ireland:a prospective multicentre observational survey. Br J Haematol. 2007;39(4):545–558. PubMed:17916101.